Total of 18656 firms and businesses for sale today Tuesday 16th April 2024
Time to Sell or Time to Buy !

Sold. Elearning Library With A Particular Emphasis On Pharmaceutical Regulatory Affairs And Compliance

LISTING DETAILS
Firms For Sale ID:
33892
Vendor reference:
CC172
Vendor website:
     
Printer Friendly
      
Contact Seller
      
Goto Website
More Like This
      
Email Search
      
Add Notes
BUSINESS DETAILS
Location:
Primary sector:
Secondary sector:
Asking price:
£1,600,000  
Turnover / revenue:
£360,000
Net profit / cashflow:
£200,000

OTHER DETAILS
Business is relocatable:
Yes
Business is web-based:
No
Business is home-based:
No
PROPERTY DETAILS
 
Image Not Found
 
 
 
Image Not Found
BUSINESS DESCRIPTION
eLearning library with a particular emphasis on Pharmaceutical Regulatory Affairs and Compliance within the pharmaceutical and biotechnology industries.
Ref.CC172
Location Relocatable
Asking Price GBP 1,600,000
Turner Butler has been appointed to invite offers of purchase for 100% of the Issued Share capital of a company that has developed an eLearning platform with a particular emphasis on Pharmaceutical Regulatory Affairs and Compliance within the pharmaceutical and biotechnology industries.
Key strengths:
The business has the following key attributes:
Powerful eLearning platform with extensive library.
Particular emphasis on Pharmaceutical Regulatory Affairs and Compliance within the pharmaceutical and biotechnology industries.
Additional generic corporate eLearning programs and bespoke development capabilities.
25 courses representing approximately 55 hours of eLearning.
Solid, longstanding international Client base including some of the biggest names in the pharmaceutical and biotechnology industries.
Three year contracts in place with some Clients.
Growth/niche business sector.
Substantial potential for course and market expansion.
Easily transportable, profitable business.
The business provides an acquirer with:
An ideal bolt on for a company already providing eLearning.
An excellent opportunity for any investor with a background in the IT or Pharmaceutical/Biotechnology industries.